Invention Grant
- Patent Title: Compound exhibiting enteropeptidase inhibitory activity
-
Application No.: US17054084Application Date: 2019-05-08
-
Publication No.: US11447480B2Publication Date: 2022-09-20
- Inventor: Young Kwan Kim , Ohhwan Kwon , Heedong Park , Junggyu Park , Hwan Geun Choi , Jung Beom Son , Eunhwa Ko , So Young Kim , Seungyeon Lee , Seock Yong Kang , Yi Kyung Ko , Jin-Hee Park
- Applicant: LG CHEM, LTD.
- Applicant Address: KR Seoul
- Assignee: LG CHEM, LTD.
- Current Assignee: LG CHEM, LTD.
- Current Assignee Address: KR Seoul
- Agency: Rothwell, Figg, Ernst & Manbeck, P.C.
- Priority: KR10-2018-0053315 20180509,KR10-2018-0053316 20180509
- International Application: PCT/KR2019/005997 WO 20190508
- International Announcement: WO2019/216742 WO 20191114
- Main IPC: C07D417/04
- IPC: C07D417/04 ; C07D277/56 ; C07D277/82

Abstract:
The present invention relates to a novel compound exhibiting enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing and treating metabolic diseases such as obesity, diabetes mellitus or hyperlipidemia, etc. comprising the compound or pharmaceutically acceptable salt, and a method for preventing or treating metabolic disease using the above novel compound. The compound of the present invention has excellent inhibitory activity against enteropeptidase, and thus is not absorbed into the body, but are excreted outside the body. However, since not only fat but also protein are discharged together, it has few side effects such as fat stools and acts only in the gastrointestinal tract, so it has few side effects such as depression, and is very useful as a therapeutic or prophylactic drug for various metabolic diseases such as obesity, diabetes mellitus, and hyperlipidemia.
Public/Granted literature
- US20210284634A1 NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITORY ACTIVITY Public/Granted day:2021-09-16
Information query